Patients with tumor cell PD‐L1 expression ≥1% treated with nivolumab plus ipilimumab continued to demonstrate improvement in median OS (13.1 months [95% CI 11.2–17.4]) versus chemotherapy (9.1 months [95% CI 7.7–10.0]) with a 38% reduction in the risk of death (HR 0.62 [95% CI 0.48–0.80]) (Figure 2A). This evidence concerns the gene CD274 and neoplasm.